|
Almeida Capital is pleased to be a premier sponsor of AltAssets
|
FREE newsletter RSS
INTELLIGENCE
RECRUITMENT
KNOWLEDGE BANK
EVENTS
SECTOR ANALYSIS
HEDGE FUNDS
|
PRINT THIS PAGE Wellington Partners hires clinical expert Dr Spigelman to strengthen life sciences team24/08/2005. Source: AltAssets. 
 Munich-based venture capital firm Wellington Partners has appointed Dr Melvin K Spigelman as a new venture partner to strengthen its life science team prior to fundraising. Wellington targets €100m with its new life science fund.
In his new role Dr Spigelman will advise Wellington Partners' portfolio companies, help select new investments and take board seats. His particular focus will be on supporting portfolio companies with respect to clinical development and approval in the US, and on forging partnerships with US companies. Dr Spigelman and Wellington Partners have worked together on selected projects since 2003.
Wellington partner Dr Rainer Strohmenger said, 'The US market stands for 50 per cent of the world pharma market. With Mel Spigelman, we now have a seasoned, outstandingly networked venture partner in the US.'
Wellington Partners founder Rolf Christof Dienst, added, 'Like virtually no one else, Mel Spigelman possesses solid expertise in the design and execution of clinical studies. It is precisely in this phase that our portfolio companies can generate the greatest added value, which means that he perfectly complements our own know-how.'
As a director of the Global Alliance for TB Drug Development, a non-profit New York organisation, Dr Spigelman is responsible for research and development in the battle against tuberculosis. He had previously held executive positions at BASF Pharma USA.
Wellington Partners invests in start-ups throughout Europe in the information and communication technology, and life science sectors. The firm manages a total fund volume of €400m.
Copyright © 2005 AltAssets
|
 
|
|
|
